查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608934

肝癌诊断市场：按测试类型和最终用户划分 - 全球预测 2025-2030

Liver Cancer Diagnostics Market by Test Type (Biopsy, Endoscopy, Imaging), End User (Academic & Research Institutes, Hospitals & Diagnostic Laboratories, Pharmaceutical & CRO Laboratories) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肝癌诊断市场价值为94.1亿美元，预计到2024年将达到100.5亿美元，复合年增长率为6.62%，到2030年将达到147.4亿美元。

肝癌诊断市场的定义是专注于开拓和实施早期准确检测肝癌的技术和方法。这个市场是必要的，因为全世界肝癌的发生率正在增加，部分原因是肝炎患者的增加和生活方式相关的危险因子。肝癌诊断药物具有广泛的治疗用途，包括筛检、早期检测和个人化治疗计划，并用于医院、诊断实验室、专科诊所和其他机构。最终用途范围从直接临床使用到研究目的。市场成长很大程度上受到显像模式、分子生物标记和液态切片活检等诊断工具技术进步的影响。此外，新兴经济体正在增加对医疗基础设施的投资，提供进一步的成长潜力。潜在的商机在于开发更多非侵入性且更具成本效益的诊断测试，以提高早期检测的准确性。公司可以利用与研究机构的伙伴关係来创新并扩大诊断工具的范围。儘管有这些奖励，但成长仍受到诊断程序成本高、低收入地区意识淡薄以及法规环境复杂等因素的挑战。此外，诊断程序中的误报和漏报可能会阻碍市场信心和采用。专注于人工智慧和机器学习以提高诊断准确性和预测分析可以推动创新。整合患者资料以製定个人化医疗保健策略的客製化诊断解决方案提供了一条有利的途径。竞争激烈且不断变化的市场要求企业保持敏捷、投资研发并快速回应监管变化。对于希望在这个动态环境中取得成功的市场参与企业来说，鼓励官民合作关係并进行宣传宣传活动以提高意识并提高筛检率也是重要的建议。

主要市场统计
基准年[2023] 94.1亿美元
预计年份 [2024] 100.5亿美元
预测年份 [2030] 147.4亿美元
复合年增长率（%） 6.62%

市场动态：揭示快速发展的肝癌诊断市场的关键市场洞察

由于供需的动态互动，肝癌诊断药物市场正在经历转型。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球肝癌发生率不断上升
    • 肝癌诊断优势报销制度
    • 增加肝癌筛检项目
  • 市场限制因素
    • 缺乏熟练且训练有素的专业人员
  • 市场机会
    • 癌症诊断设备的技术进步
    • 专注于开发有效的诊断方法
  • 市场挑战
    • 肝癌诊断药物的局限性

波特五力：驾驭肝癌诊断市场的策略工具

波特的五力框架是了解肝癌诊断市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肝癌诊断药物市场的外部影响

外部宏观环境因素在塑造肝癌诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肝癌诊断药物市场竞争状况

对肝癌诊断市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵肝癌诊断市场供应商绩效评估

FPNV定位矩阵是评估肝癌诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘肝癌诊断市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，肝癌诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球肝癌发生率增加
      • 肝癌诊断优势保险报销制度
      • 增加肝癌筛检项目
    • 抑制因素
      • 熟练且训练有素的专业人员数量有限
    • 机会
      • 癌症诊断设备的技术进步
      • 专注于开发有效的诊断方法
    • 任务
      • 肝癌诊断药物的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按测试类型分類的肝癌诊断药物市场

  • 切片检查
  • 内视镜检查
  • 影像
  • 临床检查
    • 生物标誌物
      • 酵素和同功异构酵素
      • 生长因子和受体
      • 分子标记
      • 癌胎抗原和糖蛋白抗原
      • 病理性生物标记
    • 验血

第七章肝癌诊断市场：依最终用户分类

  • 学术研究所
  • 医院和诊断实验室
  • 医药及CRO研究院

第八章北美和南美肝癌诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肝癌诊断药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲肝癌诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Accuray Incorporated
  • Biocartis NV
  • CR Bard Inc.
  • Elekta AB
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Medical Systems USA, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-3A2E844FE71E

The Liver Cancer Diagnostics Market was valued at USD 9.41 billion in 2023, expected to reach USD 10.05 billion in 2024, and is projected to grow at a CAGR of 6.62%, to USD 14.74 billion by 2030.

The liver cancer diagnostics market is defined by its focus on the development and implementation of technologies and methodologies to accurately detect liver cancer at its earliest stages. This market's necessity is driven by the increasing global incidence of liver cancer, partly due to rising cases of hepatitis and lifestyle-related risk factors. Applications of liver cancer diagnostics are wide-ranging, including screening, early detection, and personalized treatment plans, which are used by hospitals, diagnostic laboratories, and specialty clinics. The end-use scope extends from direct clinical applications to research purposes. Market growth is significantly influenced by technological advancements in diagnostic tools such as imaging modalities, molecular biomarkers, and liquid biopsy tests. Additionally, there are enhanced healthcare infrastructure investments in emerging economies, providing further growth potential. Potential opportunities lie in developing more non-invasive, cost-effective diagnostic tests that enhance early detection accuracy. Companies can capitalize on partnerships with research institutions to innovate and broaden the diagnostic tools landscape. Despite these incentives, growth is challenged by factors such as high costs of diagnostic procedures, limited awareness in low-income regions, and the regulatory environment's complexity. Furthermore, false positives or negatives in diagnostic procedures can hinder market trust and adoption. Innovation can thrive in focusing on artificial intelligence and machine learning to improve diagnostic accuracy and predictive analytics. Customized diagnostic solutions that integrate patient data for personalized healthcare strategies represent lucrative avenues. The nature of the market is competitive and continually evolving, requiring businesses to stay agile, invest in R&D, and adapt to regulatory changes swiftly. Encouraging public-private partnerships and fostering educational campaigns to heighten awareness and screening uptake are also crucial recommendations for market participants aiming to navigate and succeed within this dynamic landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 9.41 billion
Estimated Year [2024] USD 10.05 billion
Forecast Year [2030] USD 14.74 billion
CAGR (%) 6.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Incidence of liver cancer globally
    • Favorable reimbursement framework for liver cancer diagnosis
    • Growing number of liver cancer screening programs
  • Market Restraints
    • Limited skilled and trained professionals
  • Market Opportunities
    • Technological advancements in cancer diagnosis equipment
    • Focus on development of effective diagnostics
  • Market Challenges
    • Limitations of liver cancer diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Liver Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Cancer Diagnostics Market

A detailed market share analysis in the Liver Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Cancer Diagnostics Market

A strategic analysis of the Liver Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accuray Incorporated, Biocartis NV, C.R. Bard Inc., Elekta AB, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Medical Systems U.S.A., Inc., Illumina, Inc., Koninklijke Philips N.V., Myriad Genetics, Inc., Qiagen N.V., Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Biopsy, Endoscopy, Imaging, and Laboratory tests. The Laboratory tests is further studied across Biomarkers and Blood Tests. The Biomarkers is further studied across Enzymes & Isoenzymes, Growth Factors & Receptors, Molecular Markers, Oncofetal & Glycoprotein Antigens, and Pathological Biomarkers.
  • Based on End User, market is studied across Academic & Research Institutes, Hospitals & Diagnostic Laboratories, and Pharmaceutical & CRO Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence of liver cancer globally
      • 5.1.1.2. Favorable reimbursement framework for liver cancer diagnosis
      • 5.1.1.3. Growing number of liver cancer screening programs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited skilled and trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in cancer diagnosis equipment
      • 5.1.3.2. Focus on development of effective diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of liver cancer diagnostics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Biopsy
  • 6.3. Endoscopy
  • 6.4. Imaging
  • 6.5. Laboratory tests
    • 6.5.1. Biomarkers
      • 6.5.1.1. Enzymes & Isoenzymes
      • 6.5.1.2. Growth Factors & Receptors
      • 6.5.1.3. Molecular Markers
      • 6.5.1.4. Oncofetal & Glycoprotein Antigens
      • 6.5.1.5. Pathological Biomarkers
    • 6.5.2. Blood Tests

7. Liver Cancer Diagnostics Market, by End User

  • 7.1. Introduction
  • 7.2. Academic & Research Institutes
  • 7.3. Hospitals & Diagnostic Laboratories
  • 7.4. Pharmaceutical & CRO Laboratories

8. Americas Liver Cancer Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accuray Incorporated
  • 3. Biocartis NV
  • 4. C.R. Bard Inc.
  • 5. Elekta AB
  • 6. Epigenomics AG
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Fujifilm Medical Systems U.S.A., Inc.
  • 9. Illumina, Inc.
  • 10. Koninklijke Philips N.V.
  • 11. Myriad Genetics, Inc.
  • 12. Qiagen N.V.
  • 13. Siemens AG
  • 14. Sysmex Corporation
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. LIVER CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ENZYMES & ISOENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROWTH FACTORS & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR MARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ONCOFETAL & GLYCOPROTEIN ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGICAL BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & CRO LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023